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Global health initiatives rely on inter-
national solidarity. However, the ex-
treme inequity in access to vaccines for 
coronavirus disease 2019 (COVID-19) 
across countries demonstrates that we 
cannot depend on national politicians 
and industry alone to make strategic 
choices for our global common good. 
High-income countries have been ac-
cused of undermining the coordinated 
purchase and equitable distribution of 
COVID-19 vaccines through non-trans-
parent pharmaceutical deals, production 
delays and vaccine export restrictions.1 
As of 1 November 2021 fewer than 35 
million of over 7 billion COVID-19 
vaccine doses have been administered 
in low-income countries.2 Nevertheless, 
high-income countries have disregarded 
the World Health Organization’s (WHO) 
plea to pause booster doses of vac-
cines to give low- and middle-income 
countries a chance to vaccinate their 
most vulnerable populations. Despite 
these challenges, vaccine allocation 
to low- and middle-income countries 
through COVAX, the COVID-19 Vac-
cines Global Access initiative, is finally 
accelerating. Even so, only five African 
countries, fewer than 10% of its 54 na-
tions, are expected to reach the year-end 
target of fully vaccinating 40% of their 
population,3 a goal that would require 
800 million more doses of vaccine. 
Meanwhile, high-income countries 
will have over 1 billion surplus doses 
of vaccine.4
Africa currently imports 99% of its 
vaccines5 and by November 2021 fewer 
than 123 million (10%) of 1373 mil-
lion Africans have been fully or partly 
immunized against COVID-19.2 This 
deficiency in local vaccine production 
in Africa and other low- and middle-
income countries is a result of chronic 
underinvestment in research and de-
velopment, poor knowledge transfer, 
imbalanced scientific exchange and 
emigration of highly trained profession-
als. The annual loss to the African health 
sector of investment in trained doctors 
is around 2 billion United States dollars 
(US$).6 This current dependency on a 
limited number of vaccine manufactur-
ers, with just four companies controlling 
about 90% of the global vaccine market,1 
has contributed to an unsustainable 
pandemic response, a problem that was 
seen during the 2009 H1N1 influenza 
pandemic and the 2014 Ebola virus dis-
ease outbreak. As the Director-General 
of the World Trade Organization (WTO) 
declared in 2021, “We have now seen 
that over-centralization of vaccine pro-
duction capacity is incompatible with 
equitable access in a crisis situation.”7
Initiatives to reverse this trend are 
now in progress, accelerated by the 
COVID-19 pandemic. These initiatives 
include a new international treaty on 
pandemics proposed at the Seventy-
sixth session of the United Nations Gen-
eral Assembly, the new WHO Hub for 
Pandemic and Epidemic Intelligence,8 
and the Multilateral Leaders Task Force 
(comprising the World Bank, WHO, 
WTO and International Monetary 
Fund). The task force urges high-income 
countries to swap their near-term deliv-
ery schedules of COVID-19 vaccines, 
release vaccine companies from con-
tracts and fulfil their donation pledges, 
while appealing to pharmaceutical 
companies to prioritize their contracts 
with COVAX and the African Vaccine 
Acquisition Trust.9
Until recently, there were only 
10 vaccine manufacturers across five 
African countries –Egypt, Morocco, 
Senegal, South Africa and Tunisia – 
jointly producing a tiny fraction of 
the continent’s needs. Most of these 
countries have undertaken so-called 
fill and finish packaging and labelling 
with very limited upstream production 
of antigen formulations, principally 
due to a lack of local scientific capacity, 
along with weaknesses in the commod-
ity supply chain. These obstacles need 
to be removed for independence and 
sustainability of production in Africa. 
Other key barriers include regulatory 
hindrances, powerful trade blocs, scar-
city of potential purchasers, competi-
tion with subsidized markets, political 
instability, geographical and logistical 
challenges, lack of sustainable financing 
mechanisms and low economic purchas-
ing power.1,9 The COVID-19 pandemic 
is driving new production initiatives for 
vaccine hubs in Rwanda, Senegal and 
South Africa and potentially Algeria and 
Nigeria.5,7 WHO has supported tech-
nology-transfer hubs in South Africa 
to scale up production of mRNA (mes-
senger ribonucleic acid)-based vaccines 
and stimulate regional development of 
other pharmaceutical products. These 
are interesting examples of collabora-
tion between the Africa Centres For 
Disease Control and Prevention, African 
universities and pharmaceutical compa-
nies. A similar initiative is the African 
Union’s new Partnerships for African 
Vaccine Manufacturing, which aims to 
bolster vaccine manufacturing, finan-
cial partnerships, regulatory systems 
and technology transfer, with African 
universities becoming vaccine research 
and development hubs.10 However, the 
research and development goal should 
not get overlooked in the rush to set up 
new manufacturing hubs.
Regional research and develop-
ment and production of essential drugs, 
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diagnostics and vaccines in Africa is 
necessary to secure ownership and a 
sustainable supply of products and to en-
able a quicker response to future infec-
tious agents. A regional focus could also 
lead to discoveries in diagnostics and 
therapeutics for current unmet burdens 
of disease in low- and middle-income 
countries, settings of low priority for 
global pharmaceutical companies.1 Re-
searchers even argued that the price of 
locally produced vaccines could become 
lower than the price that large compa-
nies currently charge governments or 
global partners.1 We argue, however, 
that the production of essential supplies 
cannot depend on current resource 
availability. Even before the drop in 
childhood immunization coverage dur-
ing the pandemic, 9.4 million African 
children annually were not receiving 
their final dose of the diphtheria, tetanus 
and pertussis vaccine.5 When delivered 
in full, diphtheria–tetanus–pertussis 
and other vaccine programmes are 
currently estimated to save two million 
to three million children’s lives globally 
each year, a figure which highlights the 
gaps in countries’ ability both to de-
liver and to access vaccines.5 Ensuring 
regional self-sufficiency and manufac-
turing capabilities in regions with the 
highest burden of infectious diseases 
is fundamental for future pandemic 
preparedness and rapid crisis response.
The emergence of mRNA-based 
technologies could lower the threshold 
for scaling up regional manufacturing 
through reduced upfront costs and 
more rapid adaptation of vaccines to 
new variants and pathogens. Currently 
some mRNA vaccines require ultra-cold 
chain storage and distribution. Although 
future technologies may avoid this 
requirement, investments in ultra-cold 
chains for COVID-19 vaccines across 
Africa could serve multiple purposes 
if upcycled into future research labora-
tories and facilities for storage of new 
mRNA vaccines. mRNA technology also 
offers the potential to develop new or 
better vaccines, for example for malaria 
and tuberculosis. We believe that mRNA 
technology offers opportunities to Afri-
can countries, and even worldwide, that 
African researchers should be driving 
forward.
This approach could become a 
rewarding investment for companies, 
governments and funders. Assuming 
the approval of and steady demand for 
emerging vaccines, Africa’s publicly 
funded vaccine market could be worth 
between US$ 2.4–5.4 billion by 2030.5 
Africa’s demand for vaccines already 
makes up about a quarter of global 
vaccine volume and will increase with 
the estimated 2.5% annual population 
growth in the region.5 Average gross 
domestic product in Africa is also ex-
pected to grow, creating co-financing 
opportunities in countries eligible for 
support from GAVI, the Vaccine Al-
liance. The World Bank has pledged a 
600 million euro investment in Aspen 
Pharmacare, Africa’s largest pharma-
ceutical company, with support from 
the governments of France, Germany 
and the United States of America. The 
initiative aims to fund the entire vaccine 
supply chain for Africa and is part of 
the World Bank’s enhanced support for 
global vaccine rollout.5 The investment 
appears to be highly cost-effective, as 
the global economy is estimated to 
lose up to US$ 9.2 trillion due to the 
uncoordinated approach to COVID-19 
vaccine access that risks prolonging the 
pandemic.5
Despite promising advances, there 
is no guarantee that the recent technol-
ogy-transfer initiatives and research and 
development investments in Africa will 
bring about the changes needed. We as 
researchers must take on a greater re-
sponsibility to ensure that new vaccine 
technologies become a global common 
good. Achieving this aim requires long-
term investments in future local knowl-
edge and expertise. Unfortunately, the 
COVID-19 pandemic has been a setback 
to progress in education, especially in 
Africa. The impact of school closures on 
Africa’s young generations has created a 
huge backlog in education, forcing mil-
lions of children to drop out of school, 
causing trillions of dollars in lost lifetime 
incomes and opportunities. The propor-
tion of children who are out of school 
has doubled in Africa compared with 
before the pandemic11 and two thirds 
of low- and middle-income countries 
included in the World Bank’s Educa-
tion Finance Watch for 2021 reported 
education budget cuts since the onset 
of the pandemic.12
Nevertheless, the past years have 
shown that money can be made avail-
able for humanitarian and health crises, 
and that not investing in education is 
extremely costly both financially and 
socially. A lack of funding can therefore 
no longer be used as an excuse by gov-
ernments or international organizations 
not to invest in basic science education 
or in advanced biotechnology training. 
Strong support from the scientific com-
munity will be necessary to make this 
happen. We also need to mend a growing 
distrust of academics and other experts 
and reinvigorate support for evidence-
based decisions in public health, support 
which has been jeopardized during the 
COVID-19 pandemic.
Although the world’s response to 
the most recent pandemic has been a 
clear example of poor international col-
laboration, it is also an example of un-
precedented scientific success in vaccine 
innovation. The rapid development and 
production of COVID-19 vaccines is a 
great achievement for the pharmaceuti-
cal industry. Yet it is a success based on 
decades of government-funded research 
conducted primarily at universities. It is 
unacceptable that the benefits of public 
investments in scientific progress have 
been so unevenly distributed globally. 
As researchers, we have a responsibility 
to be stewards of this legacy of research, 
to apply systems thinking across the vac-
cine value chain and be neutral brokers 
between multiple actors. In global expert 
panels, we should argue for sustain-
able knowledge transfer and long-term 
investments into local research and 
development and higher education, and 
create good examples of true academic 
partnerships between high-income 
countries and low- and middle-income 
countries. For young scholars to benefit 
from the current promotion of vaccine 
production in Africa, advancements in 
legal and regulatory management and 
health economics are needed, while 
leveraging African public health profes-
sionals’ unique skills in epidemiological 
surveillance adapted to low-resource 
contexts.
The global scientific community has 
never been more active, more united or 
more motivated for research collabora-
tion and data sharing. Let us as research-
ers take the lead through a call for action 
with the goal of converting decades of 
research into vaccines for all. ■
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Corrigendum
In: Monroe A, Olapeju B, Moore S, Hunter G, Payne Merritt A, et al. Improving malaria control by understanding human behaviour. Bull World 
Health Organ. 2021 Nov 1;99(11):837–839, 
On page 839, reference 3 should read as follows: 
Kincaid DL, Storey JD, Figueroa ME, Underwood CR. Communication, ideation, and contraceptive use: the relationships observed in five 
countries. In: World Congress on Communication for Development; 2006 Oct 25–27; Rome, Italy. Washington DC: World Bank; 2007.
